StartsideNTLA • NASDAQ
add
Intellia Therapeutics Inc
Forrige sluttkurs
12,02 $
Dagsintervall
9,93 $ - 11,43 $
Årsintervall
9,93 $ - 34,87 $
Markedsverdi
1,04 mrd. USD
Gjennomsnittlig volum
2,36 mill.
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Omsetning | 9,11 mill. | −24,02 % |
Driftskostnader | 30,50 mill. | 3,73 % |
Nettoomsetning | −135,71 mill. | −11,04 % |
Netto resultatmargin | −1,49k | −46,15 % |
Fortjeneste per aksje | −1,34 | 2,90 % |
EBITDA | −142,16 mill. | −10,36 % |
Faktisk avgiftssats | — | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 658,11 mill. | −23,01 % |
Totale aktiva | 1,17 mrd. | −5,63 % |
Totale passiva | 210,74 mill. | 2,33 % |
Total egenkapital | 962,62 mill. | — |
Utestående aksjer | 101,85 mill. | — |
P/B-forhold | 1,27 | — |
Avkastning på aktiva | −30,61 % | — |
Avkastning på kapital | −33,80 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | −135,71 mill. | −11,04 % |
Kontantstrøm fra drift | −84,84 mill. | 16,32 % |
Kontanter fra investering | −7,71 mill. | −109,70 % |
Kontanter fra finansiering | 82,19 mill. | 330,28 % |
Netto kontantstrøm | −10,35 mill. | −272,58 % |
Fri kontantstrøm | −35,80 mill. | 44,08 % |
Om
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Administrerende direktør
Grunnlagt
2014
Hovedkvarter
Nettsted
Ansatte
526
